A notable study showed that patients who typically use steroid-based nasal sprays are less likely to develop severe COVID-19 related disease. In fact, this important news generated by the world-renowned Cleveland Clinic reported that of those people using the nasal spray, they were 20-25% less likely to succumb to serious COVID-19 related hospitalization, ICU admission, and death. Led by pulmonologist Joe Zein, MD, Ph.D. and allergist-immunologist and Director of the Cleveland Clinic Ronald A. Strauss, the recent study results were published in the Journal of Allergy and Clinical Immunology: In Practice. TrialSite raises the question—assuming these findings are repeatable—what if a nasal spray can be developed to maximize eradication of the SARS-CoV-2 virus in the nasal regions? What an intriguing possibility for a low-cost treatment regimen for COVID-19, particularly in low-and middle-income countries (LMICs). More study is necessary but given louder calls for treatments (and vaccines) targeting the nasal mucosal region, these findings should be widely disseminated.
Basis for the Study
Driving this Cleveland Clinic-led study was the hypothesis—based on early-stage laborator...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).